{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:51:42Z","timestamp":1784242302923,"version":"3.55.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.4065\/79.7.904","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:23:48Z","timestamp":1232760228000},"page":"904-913","source":"Crossref","is-referenced-by-count":32,"title":["The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation"],"prefix":"10.4065","volume":"79","author":[{"given":"Michael D.","family":"Ezekowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/79.7.904_bib1","author":"Centers for Medicare and Medicaid Services"},{"key":"10.4065\/79.7.904_bib2","first-page":"2242","article-title":"Preventing stroke in atrial fibrillation","volume":"56","author":"Wolf","year":"1997","journal-title":"Am Fam Physician"},{"key":"10.4065\/79.7.904_bib3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med. 1994;154:2254]","volume":"154","author":"Atrial Fibrillation Investigators","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib4","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study","volume":"147","author":"Wolf","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","article-title":"The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study","volume":"98","author":"Krahn","year":"1995","journal-title":"Am J Med"},{"key":"10.4065\/79.7.904_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"key":"10.4065\/79.7.904_bib7","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation [published correction appears in N Engl J Med. 1993;328:148]","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"10.4065\/79.7.904_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","volume":"18","author":"Connolly","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/79.7.904_bib9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","author":"EAFT (European Atrial Fibrillation Trial) Study Group","year":"1993","journal-title":"Lancet"},{"key":"10.4065\/79.7.904_bib10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation","volume":"323","author":"Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators","year":"1990","journal-title":"N Engl J Med"},{"key":"10.4065\/79.7.904_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillation Study: final results","volume":"84","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1991","journal-title":"Circulation"},{"key":"10.4065\/79.7.904_bib12","first-page":"27","article-title":"Anticoagulation and atrial fibrillation","volume":"18","author":"Atwood","year":"1993","journal-title":"Herz"},{"key":"10.4065\/79.7.904_bib13","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1001\/archinte.1996.00440210043004","article-title":"National patterns of warfarin use in atrial fibrillation","volume":"156","author":"Stafford","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.7326\/0003-4819-131-12-199912210-00004","article-title":"Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"131","author":"Go","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.4065\/79.7.904_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0735-1097(01)01587-X","volume":"38","author":"Fuster","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/79.7.904_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.7326\/0003-4819-121-1-199407010-00009","article-title":"Guidelines for medical treatment for stroke prevention","volume":"121","author":"American College of Physicians","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.4065\/79.7.904_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1212\/WNL.51.3.671","article-title":"Practice parameter: stroke prevention in patients with nonvalvular atrial fibrillation: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"51","year":"1998","journal-title":"Neurology"},{"key":"10.4065\/79.7.904_bib18","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/01.CIR.93.6.1262","article-title":"Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association","volume":"93","author":"Prystowsky","year":"1996","journal-title":"Circulation"},{"issue":"1, suppl","key":"10.4065\/79.7.904_bib19","doi-asserted-by":"crossref","first-page":"194S","DOI":"10.1378\/chest.119.1_suppl.194S","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"119","author":"Albers","year":"2001","journal-title":"Chest"},{"key":"10.4065\/79.7.904_bib20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/jama.281.12.1112","article-title":"Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association","volume":"281","author":"Gorelick","year":"1999","journal-title":"JAMA"},{"key":"10.4065\/79.7.904_bib21","series-title":"Sixth ACCP Consensus Conference on Antithrombotic Therapy: Quick Reference Guide for Clinicians","author":"American College of Chest Physicians","year":"2001"},{"key":"10.4065\/79.7.904_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0002-9149(00)01374-6","article-title":"Risk of stroke in patients with atrial flutter","volume":"87","author":"Biblo","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.4065\/79.7.904_bib23","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke-prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.4065\/79.7.904_bib24","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation","volume":"347","author":"Van Gelder","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/79.7.904_bib25","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","author":"Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/79.7.904_bib26","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0735-1097(03)00332-2","article-title":"Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study","volume":"41","author":"Carlsson","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/79.7.904_bib27","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(00)03230-X","article-title":"Rhythm or rate control in atrial fibrillation\u2014Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial","volume":"356","author":"Hohnloser","year":"2000","journal-title":"Lancet"},{"issue":"1, suppl","key":"10.4065\/79.7.904_bib28","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1378\/chest.119.1_suppl.22S","article-title":"Managing oral anticoagulant therapy","volume":"119","author":"Ansell","year":"2001","journal-title":"Chest"},{"key":"10.4065\/79.7.904_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT)","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.4065\/79.7.904_bib30","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archinte.159.12.1322","article-title":"Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 Study","volume":"159","author":"Gullov","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib31","first-page":"44","article-title":"Low incidence of hemorrhagic complications of oral anticoagulant therapy in patients with atrial fibrillation in the daily practice of an anticoagulation clinic","volume":"4","author":"Poli","year":"2003","journal-title":"Ital Heart J"},{"key":"10.4065\/79.7.904_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0002-9343(02)01131-2","article-title":"Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial","volume":"113","author":"Matchar","year":"2002","journal-title":"Am J Med"},{"key":"10.4065\/79.7.904_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00019052-200102000-00016","article-title":"Intracerebral hemorrhage: update","volume":"14","author":"Labovitz","year":"2001","journal-title":"Curr Opin Neurol"},{"key":"10.4065\/79.7.904_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"Beyth","year":"1998","journal-title":"Am J Med"},{"key":"10.4065\/79.7.904_bib35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/archinte.162.5.541","article-title":"Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation","volume":"162","author":"Man-Son-Hing","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archinte.159.7.677","article-title":"Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls","volume":"159","author":"Man-Son-Hing","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.STR.22.5.571","article-title":"Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment","volume":"22","author":"Radberg","year":"1991","journal-title":"Stroke"},{"key":"10.4065\/79.7.904_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10143-002-0222-0","article-title":"What are the actual incidence and mortality rates of intracerebral hemorrhage?","volume":"25","author":"Inagawa","year":"2002","journal-title":"Neurosurg Rev"},{"key":"10.4065\/79.7.904_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1034\/j.1600-0404.2002.1o170.x","article-title":"Site of bleeding and early outcome in primary intracerebral hemorrhage","volume":"105","author":"Arboix","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.4065\/79.7.904_bib40","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"issue":"1, suppl","key":"10.4065\/79.7.904_bib41","doi-asserted-by":"crossref","first-page":"108S","DOI":"10.1378\/chest.119.1_suppl.108S","article-title":"Hemorrhagic complications of anticoagulant treatment","volume":"119","author":"Levine","year":"2001","journal-title":"Chest"},{"key":"10.4065\/79.7.904_bib42","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1001\/jama.281.19.1830","article-title":"Preventing stroke in patients with atrial fibrillation","volume":"281","author":"Ezekowitz","year":"1999","journal-title":"JAMA"},{"key":"10.4065\/79.7.904_bib43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1525-1497.2000.04329.x","article-title":"Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anticoagulants and antiplatelet drugs","volume":"15","author":"Segal","year":"2000","journal-title":"J Gen Intern Med"},{"key":"10.4065\/79.7.904_bib44","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.4065\/79.7.904_bib45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial","volume":"348","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1996","journal-title":"Lancet"},{"key":"10.4065\/79.7.904_bib46","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.161.17.2125","article-title":"Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation","volume":"161","author":"Copland","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib47","first-page":"189","article-title":"Case records of the Massachusetts General Hospital: weekly clinicopathological exercises [published correction appears in N Engl J Med. 1996; 335:1167]","volume":"335","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/79.7.904_bib48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1046\/j.1440-1789.2000.00268.x","article-title":"Cerebral amyloid angiopathy: an overview","volume":"20","author":"Yamada","year":"2000","journal-title":"Neuropathology"},{"key":"10.4065\/79.7.904_bib49","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1212\/WNL.55.7.947","article-title":"Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study","volume":"55","author":"Rosand","year":"2000","journal-title":"Neurology"},{"key":"10.4065\/79.7.904_bib50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJM200001273420403","article-title":"Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage","volume":"342","author":"O'Donnell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4065\/79.7.904_bib51","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.53.5.1135","article-title":"MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy","volume":"53","author":"Greenberg","year":"1999","journal-title":"Neurology"},{"key":"10.4065\/79.7.904_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archneur.1987.00520130013009","article-title":"Leuko-araiosis","volume":"44","author":"Hachinski","year":"1987","journal-title":"Arch Neurol"},{"key":"10.4065\/79.7.904_bib53","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","article-title":"A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin","volume":"42","author":"Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group","year":"1997","journal-title":"Ann Neurol"},{"key":"10.4065\/79.7.904_bib54","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1212\/WNL.53.6.1319","article-title":"Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors","volume":"53","author":"Gorter","year":"1999","journal-title":"Neurology"},{"key":"10.4065\/79.7.904_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinte.160.1.41","article-title":"Why do patients with atrial fibrillation not receive warfarin?","volume":"160","author":"Bungard","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib56","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1161\/01.STR.31.6.1217","article-title":"Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission","volume":"31","author":"Cohen","year":"2000","journal-title":"Stroke"},{"key":"10.4065\/79.7.904_bib57","first-page":"301","article-title":"Physicians' perceptions of the benefits and risks of warfarin for patients with nonvalvular atrial fibrillation [letter]","volume":"165","author":"Bungard","year":"2001","journal-title":"CMAJ"},{"key":"10.4065\/79.7.904_bib58","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/pmj.76.902.783","article-title":"Implementation of antithrombotic management in atrial fibrillation","volume":"76","author":"McNulty","year":"2000","journal-title":"Postgrad Med J"},{"key":"10.4065\/79.7.904_bib59","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/archinte.160.15.2401","article-title":"The use of practitioner education and a warfarin monitoring service to improve anticoagulation practices [letter]","volume":"160","author":"Gaughan","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/clc.4960251003","article-title":"Anticoagulants for atrial fibrillation: why is the treatment rate so low?","volume":"25","author":"Buckingham","year":"2002","journal-title":"Clin Cardiol"},{"key":"10.4065\/79.7.904_bib61","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archinte.163.13.1580","article-title":"Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded","volume":"163","author":"Man-Son-Hing","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib62","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/archinte.158.19.2093","article-title":"Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation","volume":"158","author":"Brass","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib63","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.1997.00440300080006","article-title":"Atrial fibrillation and stroke prevention with warfarin in the long-term care setting","volume":"157","author":"Gurwitz","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib64","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1001\/archinte.161.20.2458","article-title":"Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting","volume":"161","author":"McCormick","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.4065\/79.7.904_bib65","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1532-5415.1999.tb01303.x","article-title":"Underuse of anticoagulation in older patients with chronic atrial fibrillation: malpractice or accuracy? [letter]","volume":"47","author":"Bellelli","year":"1999","journal-title":"J Am Geriatr Soc"},{"key":"10.4065\/79.7.904_bib66","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/01.STR.31.4.822","article-title":"Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation","volume":"31","author":"Gage","year":"2000","journal-title":"Stroke"},{"key":"10.4065\/79.7.904_bib67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1053\/hj.1999.v137.91403","article-title":"Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation","volume":"137","author":"Flaker","year":"1999","journal-title":"Am Heart J"},{"key":"10.4065\/79.7.904_bib68","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bmj.320.7246.1380","article-title":"The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis","volume":"320","author":"Protheroe","year":"2000","journal-title":"BMJ"},{"key":"10.4065\/79.7.904_bib69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/hs0102.101817","article-title":"Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project","volume":"33","author":"Lip","year":"2002","journal-title":"Stroke"},{"key":"10.4065\/79.7.904_bib70","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.282.8.737","article-title":"A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial","volume":"282","author":"Man-Son-Hing","year":"1999","journal-title":"JAMA"},{"key":"10.4065\/79.7.904_bib71","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1345\/aph.1A198","article-title":"Relationship between patients' warfarin knowledge and anticoagulation control","volume":"37","author":"Tang","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.4065\/79.7.904_bib72","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1258\/jrsm.96.4.175","article-title":"Patients' understanding of anticoagulant therapy in a multiethnic population","volume":"96","author":"Nadar","year":"2003","journal-title":"J R Soc Med"},{"key":"10.4065\/79.7.904_bib73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-133-9-200011070-00010","article-title":"A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial","volume":"133","author":"Beyth","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.4065\/79.7.904_bib74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-121-1-199407010-00008","article-title":"Medical treatment for stroke prevention","volume":"121","author":"Matchar","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.4065\/79.7.904_bib75","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/bmj.307.6917.1493","article-title":"Anticoagulation in patients with atrial fibrillation: GPs not prepared for monitoring anticoagulation [letter]","volume":"307","author":"Taylor","year":"1993","journal-title":"BMJ"},{"key":"10.4065\/79.7.904_bib76","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/j.1875-9114.1995.tb02889.x","article-title":"Outcome analysis of a pharmacist-managed anticoagulation service","volume":"15","author":"Wilt","year":"1995","journal-title":"Pharmacotherapy"},{"key":"10.4065\/79.7.904_bib77","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/ajhp\/53.13.1580","article-title":"Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions","volume":"53","author":"Lee","year":"1996","journal-title":"Am J Health Syst Pharm"},{"issue":"suppl 1","key":"10.4065\/79.7.904_bib78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1013276601930","article-title":"Anticoagulation management as a risk factor for adverse events: grounds for improvement","volume":"5","author":"Ansell","year":"1998","journal-title":"J Thromb Thrombolysis"},{"key":"10.4065\/79.7.904_bib79","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107602960100700303","article-title":"Anticoagulation: the present and future","volume":"7","author":"Van Aken","year":"2001","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.4065\/79.7.904_bib80","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1540-8183.2002.tb01047.x","article-title":"Low molecular weight heparins and glycoprotein IIb\/IIIa antagonists","volume":"15","author":"Ferguson","year":"2002","journal-title":"J Interv Cardiol"},{"key":"10.4065\/79.7.904_bib81","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/shem.2002.34092","article-title":"Direct thrombin inhibitors","volume":"39","author":"Kaplan","year":"2002","journal-title":"Semin Hematol"},{"key":"10.4065\/79.7.904_bib82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1067\/mhj.2001.116331","article-title":"Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies","volume":"142","author":"Berkowitz","year":"2001","journal-title":"Am Heart J"},{"key":"10.4065\/79.7.904_bib83","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-0037-1613445","article-title":"Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement","volume":"89","author":"Eriksson","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.4065\/79.7.904_bib84","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/79.7.904_bib85","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1538-7836.2003.00034.x","article-title":"A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I","volume":"1","author":"Eriksson","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.4065\/79.7.904_bib86","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.4065\/79.7.904_bib87","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0735-1097(03)00255-9","article-title":"Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: a dose-guiding, tolerability, and safety study","volume":"41","author":"Petersen","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.4065\/79.7.904_bib88","first-page":"239","article-title":"Ximelagatran: a long-term oral direct thrombin inhibitor for stroke and systemic embolism prevention in nonvalvular atrial fibrillation patients [abstract]","volume":"23","author":"Olsson","year":"2002","journal-title":"Eur Heart J"},{"key":"10.4065\/79.7.904_bib89","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-8703(03)00325-9","article-title":"Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)","volume":"146","author":"Halperin","year":"2003","journal-title":"Am Heart J"},{"key":"10.4065\/79.7.904_bib90","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2796.2003.01225.x","article-title":"Oral direct thrombin inhibitors in clinical development","volume":"254","author":"Gustafsson","year":"2003","journal-title":"J Intern Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611621587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611621587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T12:24:29Z","timestamp":1709987069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611621587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":90,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0025619611621587"],"URL":"https:\/\/doi.org\/10.4065\/79.7.904","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}